Groupe Hospitalier du Havre - Hôpital Jacques Monod

Verified siteinfo

France 29 Avenue Pierre Mendes France, 76290 Montivilliers, France

6 trials recruiting
Plasma cell myeloma · Rheumatoid arthritis · Systemic scleroderma
Adult patients

About Specializations

Groupe Hospitalier du Havre - Hôpital Jacques Monod in Montivilliers, France specialises in clinical trials of conditions such as Plasma cell myeloma, Rheumatoid arthritis, Systemic scleroderma, Axial spondyloarthritis, and other specialisations. This site conducts important research.

Main research areas of the site

Hematology and Oncology

The medical center is at the forefront of hematology and oncology, with a particular focus on Multiple Myeloma. The institution is dedicated to advancing treatment options for elderly patients who are newly diagnosed and ineligible for transplant.

Multiple Myeloma in Elderly Patients
Non-Frail Transplant Ineligible Populations
Innovative Combination Therapies

Through its research, the center is contributing to the development of novel therapeutic strategies, enhancing the quality of life and treatment outcomes for patients with complex hematological conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

29 Avenue Pierre Mendes France76290 MontivilliersFrance

Open in maps ↗

Recruiting now: 6 trials
Conditions studied: 10
Partner status: Verified site

More sites in Montivilliers France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

13 clinical trials

Chronic obstructive pulmonary disease

Recruiting

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ambrisentan
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Intergroupe Francophone Du Myelome

Contact Research Centre

Rheumatoid arthritis

Recruiting

Study on Rituximab for Patients with Rheumatoid Arthritis: Comparing 200 mg and 1g Doses for Maintenance Treatment

Registered drug

Study on Rituximab for Patients with Rheumatoid Arthritis: Comparing 200 mg and 1g Doses for Maintenance Treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Rituximab
Sponsor:Les Hopitaux Universitaires De Strasbourg

Contact Research Centre

Plasma cell myeloma

Recruiting

Study on Dexamethasone for Patients with Advanced Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on Dexamethasone for Patients with Advanced Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Rheumatoid arthritis

Recruiting

Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

Registered drugNo placebo

Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abatacept
Sponsor:Les Hopitaux Universitaires De Strasbourg

Contact Research Centre

Ischaemic stroke

Not yet recruiting

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Fondation A De Rothschild

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Infectious pleural effusion

Not yet recruiting

Early Saline Pleural Irrigation for Patients with Complicated Pleural Infections

Registered drugNo placebo

Early Saline Pleural Irrigation for Patients with Complicated Pleural Infections

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alteplase
Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Rituximab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Axial spondyloarthritis

Not yet recruiting

A study comparing bimekizumab and adalimumab for treating chest pain in patients with active axial spondyloarthritis who do not respond well to non-steroidal anti-inflammatory drugs.

Registered drugNo placebo